Perspectives of immune suppression in the tumor microenvironment promoting oral malignancy

June 28, 2018

Cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression. In this review, the complexity of immune-suppressive mechanisms in the tumor milieu of cancers, including oral malignancy is discussed in relation to immune check point inhibitors, regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs) and cancer associated fibrobla

Cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression. In this review, the complexity of immune-suppressive mechanisms in the tumor milieu of cancers, including oral malignancy is discussed in relation to immune check point inhibitors, regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs) and cancer associated fibroblasts (CAFs). In addition, the therapeutic approach of oral pre-cancerous disorders is mentioned. Some reports also advocate that the immunosuppressive efficacy of the oral squamous cell carcinoma (OSCC) milieu is developed in a stepwise manner depending on the stages of OSCCs. Namely, in the early stage, CAFs could be a unique effector; humoral factor(s) from OSCC cells force CAF to exert immune suppression via the direct cell contacts to effector T cells. Potentiated CAF could also affect other immune-suppressive mediators such as Treg, tumor-associated macrophages (TAMs) and MDSCs. In the advanced stage of OSCC, MDSCs could possibly be a major conductor of immune-suppression. However, how OSCCs differentially utilize the immune modulatory aspects involving CAFs, MDSCs and several other factors is not fully understood. Further elucidation of the regulatory pathways structured by tumor-host interactions could identify important therapeutic targets in OSCC development.
-end-
For more information about the article, please visit https://www.benthamopen.com/ABSTRACT/TODENTJ-12-455

Reference: Kondoh N et al, (2018). Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy, The Open Dentistry Journal. DOI: 10.2174/1874210601812010455

sts (CAFs). In addition, the therapeutic approach of oral pre-cancerous disorders is mentioned. Some reports also advocate that the immunosuppressive efficacy of the oral squamous cell carcinoma (OSCC) milieu is developed in a stepwise manner depending on the stages of OSCCs. Namely, in the early stage, CAFs could be a unique effector; humoral factor(s) from OSCC cells force CAF to exert immune suppression via the direct cell contacts to effector T cells. Potentiated CAF could also affect other immune-suppressive mediators such as Treg, tumor-associated macrophages (TAMs) and MDSCs. In the advanced stage of OSCC, MDSCs could possibly be a major conductor of immune-suppression. However, how OSCCs differentially utilize the immune modulatory aspects involving CAFs, MDSCs and several other factors is not fully understood. Further elucidation of the regulatory pathways structured by tumor-host interactions could identify important therapeutic targets in OSCC development.

For more information about the article, please visit https://www.benthamopen.com/ABSTRACT/TODENTJ-12-455

Reference: Kondoh N et al, (2018). Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy, The Open Dentistry Journal. DOI: 10.2174/1874210601812010455
-end-


Bentham Science Publishers

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.